Skip to main content
. 2017 May 7;8(29):47507–47517. doi: 10.18632/oncotarget.17670

Table 2. Demographics of 114 CHB carriers stratified according to cirrhosis status.

Cirrhosis-positive (n = 68) Cirrhosis-negative (n = 46)
HCC (n = 34) Non-HCC (n = 34) p value HCC (n = 23) Non-HCC (n = 23) p value
Age#, years 61.1 (57.7–62.9) 62.4 (57.9–62.2) 0.797 62.0 (54.2–66.7) 60.7 (53.2–68.3) 0.974
Male#, n (%) 20 (87.0%) 20 (87.0%) 1.00 28 (82.4%) 28 (82.4%) n.a.
HBeAg-ve#, n (%) 22 (95.7%) 22 (95.7%) 1.00 34 (100%) 34 (100%) n.a.
Albumin, g/L 43 (40–47) 44 (42–46) 0.309 45 (42–46) 43 (41–46) 0.458
Bilirubin, umol/L 11 (7–17) 11 (9–17) 0.927 12 (9–17) 10 (8–15) 0.183
ALT, U/L 34 (24–43) 23 (20–29) 0.002 25 (17–32) 21 (20–28) 0.692
Platelet, x 10 ^9/L 132 (91–170) 153 (125–192) 0.102 188 (166–215) 208 (174–259) 0.199
INR 1.1 (1.0–1.1) 1.1 (1.0–1.1) 0.385 1.1 (1.0–1.1) 1.0 (1.0–1.0) 0.166
AFP, ng/mL 11 (5–27) 3 (2–4) < 0.001 14 (7–53) 3 (2–3) < 0.001
Undetectable DNA#, n (%) 34 (100%) 34 (100%) 1.00 23 (100%) 23 (100%) n.a.
Duration of therapy#, years 3.4 (2.0–5.1) 3.7 (2.1–5.1) 0.652 3.2 (2.1–4.7) 3.4 (2.5–5.0) 0.582

Continuous variables expressed as median (interquartile range).

CHB, chronic hepatitis B virus; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; INR, international normalised ratio; AFP, alpha-fetal protein.

# Matched variables.

n.a., p-value not applicable as these were matched categorical variable.